The Board has approved allotment of 7,240 (Seven Thousand Two Hundred Forty) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employees of the Company, upon exercise ....
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare Solutions' Board approved multiple items at its May 25, 2026 meeting. Key decisions included audited FY2026 results with an unmodified opinion. Standalone FY2026 revenue was Rs 3,482.41M (vs Rs 4,086.70M YoY), with PAT of Rs 268.75M (vs Rs 191.81M YoY). Consolidated FY2026 revenue was Rs 65,912.12M (vs Rs 50,957.80M YoY) with PAT of Rs 1,458.40M, up 35.7% YoY. The Board approved allotment of 7,240 equity shares to eligible employees upon exercise of vested options under the Entero Employee Stock Option Plan 2023, and separately granted 7,300 fresh ESOPs. Three independent directors were re-appointed for a second term (subject to shareholder approval at the 8th AGM on August 19, 2026). The company also approved acquisition of Vishal Surgicals and Vishal Surgicals & Medicals (partnership firm) via its subsidiary Sai Pharma Distributors Private Limited through a Business Transfer Agreement. IPO proceeds remain fully deployed.
The company posted strong consolidated profit growth and is expanding through acquisitions and ESOP incentives, which is positive for long-term alignment. However, standalone revenue declined YoY due to subsidiary restructuring and one-time labour code compliance charges (Rs 44.97M exceptional item). ESOP dilution is minimal at 7,240 shares.